SSI(SZ:002742)2019-10-22 16:00Financial Performance - Operating revenue for the reporting period was CNY 720,919,576.52, an increase of 42.19% year-on-year [7]. - Net profit attributable to shareholders was CNY 4,987,319.94, a decrease of 51.50% compared to the same period last year [7]. - Net cash flow from operating activities was CNY 19,156,816.18, down 51.06% year-on-year [7]. - Total operating revenue for the third quarter was CNY 720,919,576.52, an increase of 42.1% compared to CNY 507,006,234.97 in the same period last year [36]. - Net profit for the period was CNY 5,163,044.75, a decrease of 62.7% from CNY 13,860,926.59 in the previous year [37]. - The net profit for the third quarter was a loss of CNY 24,377,257.13, compared to a loss of CNY 7,423,694.43 in the previous year, indicating a deterioration in performance [42]. - The net profit for the year-to-date period was CNY 102,743,175.65, an increase from CNY 99,066,852.32, indicating a positive trend [45]. - The total comprehensive income for the third quarter was CNY 15,197,350.69, a decrease from CNY 19,889,130.02 in the previous year [38]. - The total comprehensive income attributable to the parent company was ¥79,801,039.03, down from ¥92,365,508.15 in the previous period [46]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 5,000,029,441.82, a decrease of 0.74% compared to the end of the previous year [7]. - The company's total assets decreased to CNY 3,878,366,109.89 from CNY 4,139,368,149.89, reflecting a decline of 6.3% [34]. - Total liabilities decreased to CNY 2,676,203,055.50 from CNY 2,873,081,605.94, a reduction of 6.9% [33]. - Total liabilities decreased to ¥3.19 billion from ¥3.28 billion, showing a reduction of approximately 2.7% [28]. - The company's equity attributable to shareholders increased to ¥1.55 billion from ¥1.51 billion, marking a growth of about 2.3% [29]. Cash Flow - Cash and cash equivalents increased by 32.92% to CNY 505,908,543.72, attributed to improved collection management [15]. - The company's cash and cash equivalents increased to CNY 465,722,155.68 from CNY 334,290,433.28, representing a growth of 39.3% [31]. - The net cash flow from operating activities was ¥74,464,417.47, a recovery from a negative cash flow of -¥56,437,110.22 in the previous period [53]. - The total cash inflow from operating activities was ¥1,988,061,756.31, compared to ¥1,436,267,804.60 in the previous period, reflecting stronger operational performance [53]. - The net cash flow from financing activities was negative at -¥111,957,076.81, contrasting with a positive cash flow of ¥171,034,384.82 in the previous period [58]. Research and Development - Research and development expenses increased by 68.74% to CNY 24,999,382.45, indicating a focus on innovation [15]. - Research and development expenses increased to CNY 5,523,216.89, up from CNY 3,057,322.15, reflecting a focus on innovation [40]. - Research and development expenses increased to ¥16,737,468.47 from ¥10,756,828.49, showing a commitment to innovation [49]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 24,951 [11]. - The top shareholder, Pan Xianwen, holds 49.37% of the shares, with 159,971,182 shares pledged [11]. Strategic Initiatives - The company is actively seeking to extend its gypsum mining rights and is exploring purchasing gypsum from nearby areas to ensure production continuity [17]. - The company plans to increase investment in the pharmaceutical industry and accelerate its internationalization strategy to enhance profit contributions [17]. - The company aims to adjust its overall strategic planning based on actual conditions to ensure steady growth in revenue and profit [17]. Inventory and Receivables - Accounts receivable rose to ¥1.54 billion, up from ¥1.50 billion, indicating a slight increase of about 2.5% year-over-year [26]. - The company's inventory increased to ¥358.34 million from ¥298.28 million, reflecting a growth of approximately 20.2% [26]. - The company's inventory decreased to CNY 56,219,839.81 from CNY 67,187,112.66, a decline of 16.4% [31].